PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

About this update from Pfizer, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":212,"url":"https://media.zenfs.com/en/business-wire.com/da375dd0679497dde84fd49445e9d5b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Q08eHBHP._fLuep0.TmoBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/da375dd0679497dde84fd49445e9d5b6","width":480,"height":212}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease at surgery","length":209,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The results, combined with the recent unprecedented data from the EV-303 trial, highlight the potential for this regimen to become a new standard of care for muscle-invasive bladder cancer patients, regardless of cisplatin eligibility","length":234,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"First and only platinum-free regimen to significantly improve event-free and overall survival when used before and after surgery","length":128,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":571,"olType":false},{"type":"text","content":"NEW YORK & TOKYO, February 27, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative (before and after surgery) enfortumab vedotin plus pembrolizumab demonstrated a 47% reduction in the risk of tumor recurrence, progression or death compared to patients treated with standard of care neoadjuvant (before surgery) gemcitabine and cisplatin (Hazard Ratio (HR) of 0.53; 95% Confidence Interval (CI), 0.41–0.70; 1-sided p<.0001).i An estimated 79.4% of patients were event-free at two years, relative to 66.2% treated wit...

More updates from Pfizer, Inc.